FORM PTO-1449 — U.S. Dept. of Commerce, Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
ARH	1	4,968,603	06.11.90	Slamon et al.			
	2	5,183,884	02.02.93	Kraus et al.			
	3	5,480,968	02.01.96	Kraus et al.			
	4	5,641,869	24.06.97	Vandlen et al.			
	5	5,677,171	14.10.97	Hudziak et al.			
	6	5,783,186	21.07.98	Arakawa et al.			
	7	5,821,337	13.10.98	Carter et al.			
	8	5,824,311	20.10.98	Greene et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
ARH	9	599,274	01.06.94	EPO				
	10	WO 90/14357	29.11.90	PCT				
	11	WO 92/20798	26.11.92	PCT				
	12	WO 94/00136	06.01.94	PCT				
	13	WO 94/22478	13.10.94	PCT				
	14	WO 97/35885	02.10.97	PCT				
	15	WO 98/02540	22.01.98	PCT				
	16	WO 98/02541	22.01.98	PCT				
	17	WO 98/17797	30.04.98	PCT				
	18	WO 99/39729	12.08.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ARH	19	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" British Journal of Cancer 57(4):358-363 (Apr 1988)
	20	Akiyama et al., "Tumor Promoter and Epidermal Growth Factor Stimulate Phosphorylation of the c-erbB-2 Gene Product in MKN-7 Human Adenocarcinoma Cells" Molecular & Cellular Biology 8(3):1019-1026 (Mar 1988)
	21	Arteaga et al., "p185$^{c\text{-}erbB\text{-}2}$ Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" Cancer Research 54(14):3758-3765 (Jul 15, 1994)
	22	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" Molecular Carcinogenesis 3(6):350-362 (1990)
	23	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" Cancer Research 52(9):2580-2589 (May 1, 1992)
	24	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185^{HER2} Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" J. Clin. Oncol. 14(3):737-744 (Mar 1996)
	25	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" Pharmac. Ther. 64:127-154 (1994)
	26	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" Gynecologic Oncology 38(3):364-366 (Sep 1990)

Examiner: [signature] — Date Considered: 12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ACH	27	Burden et al., "Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis" Neuron 18(6):847-855 (Jun 1997)
	28	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" Cell 78:5-8 (Jul 15, 1994)
	29	Carraway et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" Nature 387:512-516 (May 1997)
	30	Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy" Proc. Natl. Acad. Sci. 89:4285-4289 (May 1992)
	31	Chang et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" Nature 387:509-512 (May 29, 1997)
	32	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185^{neu}) in normal and transformed epithelial tissues of the digestive tract" Oncogene 4(1):81-88 (Jan 1989)
	33	Connelly et al., "The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade" Proc. Natl. Acad. Sci. USA 87:6054-6057 (Aug 1990)
	34	Craft et al., "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase" Nature Medicine 5(3):280-285 (Mar 1999)
	35	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" Proc. Natl. Acad. Sci. USA 91(15):7202-7206 (Jul 19, 1994)
	36	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" Cell 41(3):695-706 (Jul 1985)
	37	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" Oncogene 2:273-277 (1988)
	38	Earp et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" Breast Cancer Res and Treatment 35:115-132 (1995)
	39	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" Cancer Research 50:1550-1558 (Mar 1, 1990)
	40	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" Molecular & Cellular Biology 6(3):955-958 (Mar 1986)
	41	Goldman et al., "Heterodimerization of the erbB-1 and erbB-2 Receptors in Human Breast Carcinoma Cells: A Mechanism for Receptor Transregulation" Biochemistry 29(50):11024-11028 (1990)
	42	Graus-Porta et al., "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling" EMBO Journal 16(7):1647-1655 (1997)
	43	Groenen et al., "Structure-Function Relationships for the EGF/TGF-α Family of Mitogens" Growth Factors 11:235-257 (1994)
	44	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" Cancer Lett. 99:185-189 (1996)
	45	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" Oncogene Res 3:21-31 (1988)
✓	46	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" Cancer Research 51:4575-4580 (Sep 1, 1991)

Examiner [signature] Date Considered 12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1467R2	Serial No. 09/602,812
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.	
		Filing Date 23 Jun 2000	Group To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AH	47	Harari et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" Oncogene 18:2681-2689 (1999)
	48	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" Journal of Biological Chemistry 267(21):15160-15167 (Jul 25, 1992)
	49	Holmes et al., "Identification of Heregulin, a Specific Activator of p185^{erbB2}" Science 256:1205-1210 (May 22, 1992)
	50	Hudziak et al., "Increased expression of the putative growth factor receptor p185^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells" Proc. Natl. Acad. Sci. 84(20):7159-7163 (Oct 1987)
	51	Hudziak et al., "p185^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" Molecular & Cellular Biology 9(3):1165-1172 (Mar 1989)
	52	Jones et al., "Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis" Journal of Biological Chemistry 273(19):11667-11674 (May 8, 1998)
	53	Kannan et al., "Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells" Journal of Biological Chemistry 272(6):3330-3335 (Feb 7, 1997)
	54	Karunagaran et al., "ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer" EMBO Journal 15(2):254-264 (1996)
	55	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" Cancer Research 52(10):2771-2776 (May 15, 1992)
	56	Kern et al., "p185^{neu} Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" Cancer Research 50(16):5184-5191 (Aug 15, 1990)
	57	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" Science 229:974-976 (Sept 1985)
	58	King et al., "EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3" EMBO Journal 7(6):1647-1651 (1988)
	59	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" Oncogene 14:2099-2109 (1997)
	60	Kokai et al., "Synergistic Interaction of p185c-neu and the EGF Receptor Leads to Transformation of Rodent Fibroblasts" Cell 58:287-292 (Jul 28, 1989)
	61	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" In Vitro (Abstract #176) 26(3):59A (1990)
	62	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" FASEB Journal (abstract #1470) 4(7):A1946 (1990)
	63	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-gamma and Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (Program 1470, Joint Mtg of ASBMB & AAI in New Orleans, LA on June 4-7, 1990 poster)
	64	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" Proc. Natl. Acad. Sci. USA 86:9193-9197 (Dec 1989)
	65	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" Molecular & Cellular Biology 11(2):979-986 (Feb 1991)
	66	Lee et al., "Transforming Growth Factor α: Expression, Regulation, and Biological Activities" Pharmacological Reviews 47(1):51-85 (Mar 1995)

Examiner	Date Considered
Anne L. Hallenbeck	12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Alt	67	Lemke,G., "Neuregulins in Development" Molecular and Cellular Neuroscience 7:247-262 (1996)
	68	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" J. Neuroscience 15(2):1329-1340 (Feb 1995)
	69	Lewis et al., "Differential responses of human tumor cell lines to anti-p185^{HER2} monoclonal antibodies" Cancer Immunol. Immunother. 37:255-263 (1993)
	70	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" Cancer Research 56:1457-1465 (Mar 15, 1996)
	71	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" Cancer Research 51(19):5361-5369 (Oct 1, 1991)
	72	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" Cancer Research 44(3):1002-1007 (Mar 1984)
	73	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" Cancer 65(1):88-92 (Jan 1, 1990)
	74	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" Oncogene 4:543-548 (1989)
	75	"Could Medarex's MAb be prostate cancer's Herceptin?" Scrip 2442:25 (Jun 2, 1999)
	76	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185^{erbB2}" Proc. Natl. Acad. Sci. USA 92:1431-1435 (Feb 1995)
	77	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185^{neu}" Methods in Enzymology 198:277-290 (1991)
	78	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" Cancer Research 49(23):6605-6609 (Dec 1, 1989)
	79	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" Oncogene 9:1829-1838 (1994)
	80	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180^{erbB4}" Nature (Letters to Nature) 366:473-475 (Dec 2, 1993)
	81	Plowman et al., "Ligand-specific activation of HER4/p180^{erbB4}, a fourth member of the epidermal growth factor receptor family" Proc. Natl. Acad. Sci. USA 90:1746-1750 (Mar 1993)
	82	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" Cancer Research 57(20):4593-4599 (Oct 15, 1997)
	83	Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" Hum. Pathol. 28(7):827-833 (July 1997)
	84	Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma" Cancer 79(11):2162-2170 (June 1, 1997)
	85	Sadasivan et al., "Overexpression of Her-2/Neu May Be An Indicator of Poor Prognosis in Prostate Cancer" J. Urol. 150:126-131 (Jul 1993)
	86	Sarup et al., "Characterization of an Anti-P185^{HER2} Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" Growth Regulation 1:72-82 (1991)

Examiner	Date Considered
[signature]	12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AH	87	Schaefer et al., "A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2" Journal of Biological Chemistry 274(2):859-866 (Jan 8, 1999)
	88	Schaefer et al., "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" Oncogene 15:1385-1394 (1997)
	89	Scher et al., "Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor α in the Progression of Prostatic Neoplasms" Clinical Cancer Research 1:545-550 (May 1995)
	90	Scott et al., "p185^{HER2} Signal Transduction in Breast Cancer Cells" Journal of Biological Chemistry 266(22):14300-14305 (Aug 5, 1991)
	91	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" Cancer Research 54(5):1367-1373 (Mar 1, 1994)
	92	Sheng et al., "Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2" J. Clin. Invest. 99(9):2254-2259 (May 1997)
	93	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" J. Clin. Immunol. 11(3):117-127 (1991)
	94	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" Science 235:177-182 (Jan 9, 1987)
	95	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" Science 244:707-712 (May 12, 1989)
	96	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" Journal of Biological Chemistry 269(20):14661-14665 (May 20, 1994)
	97	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" Proc. Natl. Acad. Sci. USA 88(19):8691-8695 (Oct 1, 1991)
	98	Stern et al., "EGF-stimulated Tyrosine Phosphorylation of p185^{neu}: a potential model for receptor interactions" EMBO Journal 7(4):995-1001 (1988)
	99	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185^{HER2} and growth inhibition of cells with HER2/NEU gene amplification" International Journal of Cancer 47(6):933-937 (Apr 1, 1991)
	100	Vadlamudi et al., "Regulation of Cyclooxygenase-2 pathway by HER2 receptor" Oncogene 18:305-314 (1999)
	101	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" Cancer Research 54(20):5301-5309 (Oct 15, 1994)
	102	Wada et al., "Intermolecular Association of the p185^{neu} Protein and EGF Receptor Modulates EGF Receptor Function" Cell 61:1339-1347 (Jun 29, 1990)
	103	Weiner et al., "Expression of the neu Gene-encoded Protein (P185^{neu}) in Human Non-Small Cell Carcinomas of the Lung" Cancer Research 50(2):421-425 (Jan 15, 1990)
	104	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" J. of Immunology 157:4986-4995 (1996)
	105	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" Pathobiology 59(1):46-52 (1991)
	106	Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens" Selected Methods in Cellular Immunology, Mishel and Schiigi, eds., San Francisco:WJ Freeman Co., Chapter 13, pps. 287-304 (1980)

Examiner [signature] Date Considered 12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RN1+	107	Worthylake et al., "Structural Aspects of the Epidermal Growth Factor Receptor Required for Transmodulation of erbB-2/neu" Journal of Biological Chemistry 272(13):8594-8601 (Mar 28, 1997)
	108	Wright et al., "An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-defective Epidermal Growth Factor Receptors" Journal of Biological Chemistry 270(20):12085-12093 (May 19, 1995)
	109	Wu et al., "Apoptosis Induced By an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in a Human Colorectal Carcinoma Cell Line and Its Delay By Insulin" Journal of Clinical Investigation 95(4):1897-1905 (Apr 1995)
	110	Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185" International Journal of Cancer 53(3):401-408 (Feb 1, 1993)
	111	Yeh et al., "From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells" Proc. Natl. Acad. Sci. USA 96:5458-5463 (May 1999)
	112	Yokota et al., "Amplification of c-erbB-2 Oncogene in Human Adenocarcinomas in Vivo" Lancet 1(8484):765-767 (Apr 5, 1986)
	113	Yonemura et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer" Cancer Research 51(3):1034-1038 (Feb 1, 1991)
	114	Zhang et al., "Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4" Proc. Natl. Acad. Sci. USA 94:9562-9567 (Sep 22, 1997)
	115	Zhau et al., "Amplification and Expression of the c-erb B-2/neu Proto-Oncogene in Human Bladder Cancer" Molecular Carcinogenesis 3(5):254-257 (1990)

Examiner [signature] Date Considered 12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant: Adams et al.	
Filing Date: 23 Jun 2000	Group: 1644

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
Arlt	219	WO 00/69460	23.11.00	PCT				
Arlt	220	WO 01/00238 A1	04.01.01	PCT				
Arlt	221	WO 01/00244 A2	04.01.01	PCT				
Arlt	222	WO 01/15730 A1	08.03.01	PCT				

Examiner: Anne L. Holleran

Date Considered: Oct. 21, 2002

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 | U.S. Dept. of Commerce, Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant	
Adams et al.	
Filing Date	**Group**
23 Jun 2000	1642

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
AL/H	223	WO 00/61145	19.10.00	PCT				

Examiner: [signature]

Date Considered: 12/22/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant: Adams et al.	
Filing Date: 23 Jun 2000	Group: 1642

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
ACH	~~226~~	WO 00/78347	28.12.00	PCT				

Examiner: Anne L. Hellerman Date Considered: Oct 21, 2002

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1467R2	09/602,812
Applicant: Adams et al.	
Filing Date: 23 Jun 2000	Group: 1642

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AcH	227	Ahmed., "A New Rapid and Simple Non-Radioactive Assay to Monitor and Determine the Proliferation of Lymphocytes: An Alternative to [3H]Thymidine Incorporation Assay." J. Immunol. Methods 170:211-224 (1994)
AcH	228	Baca et al., "Antibody Humanization Using Monovalent Phage Display" Journal of Biological Chemistry 272(16):10678-10684 (1997)
AcH	229	Bos, Johannes L., "A Target for Phosphoinositide 3-Kinase: Akt/PKB" Trends Biochem. Sci. 20:441-442 (Nov 1995)
AcH	230	Carraway et al., "Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3" J. Bio. Chem. 270:7111-7116 (Mar 1995)
AcH	231	Krymskaya et al., "EGF Activates ErbB-2 and Stimulates Phosphatidylinositol 3-Kinase in Human Airway Smooth Muscle Cells." Am. J. Physiol. 276:L246-L255 (1999)
AcH	232	Olayioye et al., "ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent Upon Their Dimerization Partner." Molecular & Cellular Biology 18:5042-5051 (Sep 1998)
AcH	233	Page et al., "A New Fluorometric Assay for Cytotoxicity Measurements In Vitro." Int. J. Oncol. 3:473-476 (1993)
AcH	234	Sugarman et al., "Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro" Science 230:943-945 (1985)
AcH	235	Tan et al., "Heregulin β1-Activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-Regulated Kinase." Cancer Research. 59:1620-1625 (Apr 1999)

Examiner: Anne L Hallman

Date Considered: 11/17/2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.